Nautilus Biotechnolgy/$NAUT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nautilus Biotechnolgy
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
- Ticker
- $NAUT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 128
- Headquarters
- Seattle, United States
- Website
- www.nautilus.bio
NAUT Metrics
BasicAdvanced
$308M
-
-$0.46
0.73
-
Price and volume
Market cap
$308M
Beta
0.73
52-week high
$4.31
52-week low
$0.84
Average daily volume
10M
Financial strength
Current ratio
9.247
Quick ratio
8.872
Long term debt to equity
0.194
Total debt to equity
0.229
Profitability
EBITDA (TTM)
-62.759
Gross margin (TTM)
90.80%
Net profit margin (TTM)
-13,816.75%
Operating margin (TTM)
-15,105.66%
Management effectiveness
Return on assets (TTM)
-22.88%
Return on equity (TTM)
-41.01%
Valuation
Price to revenue (TTM)
724.117
Price to book
2.64
Price to tangible book (TTM)
2.64
Price to free cash flow (TTM)
-5.568
Free cash flow yield (TTM)
-17.96%
Free cash flow per share (TTM)
-0.435
Growth
Earnings per share change (TTM)
-7.27%
3-year earnings per share growth (CAGR)
-1.34%
What the Analysts think about NAUT
Analyst ratings (Buy, Hold, Sell) for Nautilus Biotechnolgy stock.
Analyst projections of the future price of Nautilus Biotechnolgy stock.
Bulls say / Bears say
A peer-reviewed Nature Methods study gives the platform meaningful technical validation: Nautilus reported quantifying 130 tau proteoform groups, including forms present at 0.1% of samples, with a median coefficient of variation below 5.5%. (Nature)
The early-access programme has moved beyond research collaborations to initial paid work: Nautilus recorded its first service revenue in Q2 and named Baylor College of Medicine as its first platform customer. This is an early, not yet material, sign of customer demand. (Nautilus Biotechnology)
Nautilus expects to take part in an ARPA-H-funded research consortium, with up to $6 million potentially payable to the company after contracting. If completed, the work would provide a funded application for Voyager in Alzheimer’s disease and cancer research. (Nautilus Biotechnology)
The broadscale assay failed to meet Nautilus’s target performance for a 2027 launch, and the company gave no replacement commercial timeline. It also moved expected Voyager instrument shipments to mid-2027, delaying the broader commercial opportunity. (Nautilus Biotechnology, GenomeWeb)
Commercial traction remains very small: Q2 revenue was just $0.2 million, while the company recorded a $14.5 million net loss. It therefore remains far from showing that product sales can cover its development costs. (Nautilus Biotechnology)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
NAUT Financial Performance
Revenues and expenses
NAUT Earnings Performance
Company profitability
Upcoming events
No upcoming events
NAUT News
AllArticlesVideos
Funds containing NAUT
Fund name | Fund size | $NAUT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.